New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 12, 2013
12:13 EDTHNZ, NCT, APKT, EXAS, DELL, ZIOPOptions with increasing implied volatility: ZIOP EXAS NCT DELL APKT HNZ
News For ZIOP;EXAS;NCT;DELL;APKT;HNZ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 28, 2015
15:32 EDTEXASExact Sciences announces Norton Healthcare to adopt Cologuard
Exact Sciences announced Norton Healthcare is the first healthcare system in Kentucky to offer Cologuard, the first and only FDA-approved noninvasive stool DNA screening test for colorectal cancer. Cologuard makes it easy for average risk patients 50 years and older to get screened at their convenience and in the privacy and comfort of their own home without having to worry about taking time off work to prepare for an invasive procedure. “Norton Healthcare is proud to be the first healthcare provider in Kentucky to offer this important new advancement that can help increase screening compliance for colon cancer,” said Dr. Thomas Woodcock, an Oncology Specialist with the Norton Healthcare Cancer Institute. “The decision to offer this at-home screening tool reflects the commitment of the Norton Cancer Institute to lead the way in innovative cancer care and prevention.”
January 27, 2015
10:54 EDTZIOPZiopharm February volatility elevated at 135
Subscribe for More Information
January 20, 2015
13:21 EDTZIOPCAR T-Cell therapy drug stocks down sharply following NY Times story
Shares of biotechnology companies that are developing chimeric antigen receptor T cells or CAR T therapy drugs are falling sharply after a New York Times story titled "Riding High, Biotech Firms Remain Wary." WHAT'S NEW: Over the weekend, the New York Times published the story that struck a cautionary tone on the CAR-T therapy drugs. In this form of cancer treatment the patients own immune system cells are genetically manipulated to battle tumors. The New York Times story noted that there were some notable outcomes in the treatment of leukemia and lymphoma with the CAR T treatments but highlighted that the "technique is still early in development and can cause severe side effects." WHAT'S NOTABLE. Early last week, Intrexon (XON) and its oncology partner, ZIOPHARM Oncology (ZIOP), announced an exclusive licensing agreement with The University of Texas MD Anderson Cancer Center, including an exclusive sub-licensing agreement through MD Anderson for intellectual property developed at the University of Minnesota for the development of non-viral adoptive cellular cancer immunotherapies. Both companies' shares were up sharply following the announcement ZIOPHARM was up around 55% and Intrexon up over 30% the day following the announcement. PRICE ACTION: Shares of drug companies in the space are sharply lower in midday trading, with ZIOPHARM Oncology and Kite Pharma (KITE) each down over 9%, Intrexon down almost 12%, and Bellicum Pharmaceutical (BLCM) and bluebird bio (BLUE) each down almost 5%. Reference Link
05:54 EDTZIOPStocks with implied volatility movement; ZIOP INVN
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use